浏览全部资源
扫码关注微信
匹多莫德辅助治疗手足口病合并细菌感染的疗效观察
Efficacy of pidotimod as an adjuvant treatment for hand-foot-and-mouth disease complicated with bacterial infection
- 保健医学研究与实践 2018年15卷第3期 页码：50-54
- 作者机构：
大冶市人民医院感染科
- 作者简介：
- 基金信息：
DOI：
中图分类号： R725.1纸质出版日期：2018，
扫 描 看 全 文
[1]曹慧.匹多莫德辅助治疗手足口病合并细菌感染的疗效观察[J].保健医学研究与实践,2018,15(03):50-54.
Cao Hui. Efficacy of pidotimod as an adjuvant treatment for hand-foot-and-mouth disease complicated with bacterial infection[J]. Health Medicine Research and Practice, 2018,15(3):50-54.
摘要
目的探讨匹多莫德辅助治疗手足口病（HFMD）合并细菌感染的疗效。方法选取2012年6月-2015年5月湖北省某医院收治的84例HFMD患儿为研究对象。采用随机数字表法将患儿分为观察组和对照组
每组42例。对照组患儿采用常规治疗
观察组患儿在对照组治疗基础上加用匹多莫德口服溶液治疗。比较治疗前后2组患儿C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）及白介素-10（IL-10）水平、T淋巴细胞亚群（CD3+
CD
4
+
CD
8
+
细胞百分率及CD
4
+
/CD
8
+
比值）变化情况;比较2组患儿治疗期间不良反应发生情况、体温恢复正常时间、疱疹消退时间及住院时间。结果治疗前
2组患儿CRP
TNF-α
IL-6及IL-10水平比较
差异无统计学意义（P
>
0.05）。治疗后
2组患儿CRP
TNF-α
IL-6及IL-10水平均低于治疗前
且观察组患儿低于对照组
差异均有统计学意义（P
<
0.05）。治疗前
2组患儿CD3+
CD
4
+
CD
8
+
细胞百分率及CD
4
+
/CD
8
+
比值比较
差异无统计学意义（P
>
0.05）。治疗后
观察组患儿CD
8
+
细胞百分率低于治疗前
而CD3+
CD
4
+
细胞百分率及CD
4
+
/CD
8
+
比值高于治疗前
差异均有统计学意义（P
<
0.05）。治疗后
观察组患儿CD
8
+
细胞百分率低于对照组
而CD3+
CD
4
+
细胞百分率及CD
4
+
/CD
8
+
比值高于对照组
差异均有统计学意义（P
<
0.05）。治疗前后
对照组患儿CD3+
CD
4
+
CD
8
+
细胞百分率及CD
4
+
/CD
8
+
比值比较
差异无统计学意义（P
>
0.05）。观察组患儿治疗总有效率为92.86%
高于对照组的73.81%
差异有统计学意义（P
<
0.05）。观察组患儿体温恢复时间、疱疹消退时间、口腔溃疡消退时间及住院时间均短于对照组
差异均有统计学意义（P
<
0.05）。治疗期间
2组患儿均未发生任何不良反应。结论匹多莫德辅助治疗HFMD合并细菌感染
可改善患儿临床症状、提高患儿免疫功能
安全性高
疗效确切
值得临床推广应用。
Abstract
Objective To assess the efficacy of pidotimod as an adjuvant treatment for hand-foot-and-mouth disease（HFMD）complicated with bacterial infection.Methods A total of 84 children with HFMD treated at a hospital in Hubei Province from June 2012 to May 2015 were included in this study.Using a random number table
children were divided into the trial group and the control group
42 children in each group.Children in the control group received conventional treatment
while those in the trial group received pidotimod oral solution in addition to conventional treatment.Both pre-and post-treatment levels of CRP
TNF-α
IL-6
and IL-10
as well as T cell subsets（proportions of CD3+
CD
4
+
CD
8
+
cells
and CD
4
+
/CD
8
+
ratio）were measured and compared between the two groups.Besides
the incidence of adverse events
time to normalization of body temperature
time to resolution of herpes
and length of hospital stay were also compared between the two groups.Results Before treatment
the CRP
TNF-α
IL-6
and IL-10 levels were comparable between the two groups（P
>
0.05）.After treatment
the CRP
TNF-α
IL-6
and IL-10 levels were reduced in both groups compared with their pre-treatment levels;those in the trial group were significantly lower than those in the control group（P
<
0.05）.Before treatment
the proportions of CD3+
CD
4
+
CD
8
+
cells
and CD
4
+
/CD
8
+
ratio were similar between the two groups（P
>
0.05）.After treatment
the proportion of CD
8
+
cells was decreased and the proportions of CD3+and CD
4
+
cells and the CD
4
+
/CD
8
+
ratio were increased in the trial group compared with their pre-treatment values and those in the control group（P
<
0.05）.The proportions of CD3+
CD
4
+
CD
8
+
cells
and CD
4
+
/CD
8
+
ratio remained similar before and after treatment（P
>
0.05）.The overall response rate in the trial group was significantly higher than that in the control group（92.86% vs 73.81%
P
<
0.05）.Moreover
the time to normalization of body temperature
time to resolution of herpes
time to resolution of oral ulcers
and length of hospital stay were significantly shorter than those in the control group（P
<
0.05）.No adverse events were reported during treatment in both groups.Conclusion As an adjuvant treatment for HFMD complicated with bacterial infection
pidotimod appears to be safe and effective in improving clinical symptoms and enhancing immunity
which deserves widespread clinical application.
关键词
匹多莫德手足口病细菌感染免疫功能
Keywords
PidotimodHand-foot-and-mouth diseaseBacterial infectionImmunity
references
0
浏览量
21
下载量
1
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
